Banque Pictet & Cie SA Purchases 80,851 Shares of Edwards Lifesciences Co. (NYSE:EW)

Banque Pictet & Cie SA increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 106.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 156,968 shares of the medical research company’s stock after buying an additional 80,851 shares during the period. Banque Pictet & Cie SA’s holdings in Edwards Lifesciences were worth $11,620,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Bowman & Co S.C. lifted its position in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares in the last quarter. Mount Yale Investment Advisors LLC lifted its position in Edwards Lifesciences by 1.9% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after buying an additional 162 shares in the last quarter. JFS Wealth Advisors LLC lifted its position in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. Seascape Capital Management grew its holdings in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after acquiring an additional 174 shares in the last quarter. Finally, Cooper Financial Group grew its stake in Edwards Lifesciences by 2.8% in the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after purchasing an additional 175 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,750 shares of company stock worth $1,564,255. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.2 %

Shares of NYSE EW opened at $75.96 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a 50-day moving average price of $72.51 and a 200-day moving average price of $69.36. The stock has a market capitalization of $44.80 billion, a P/E ratio of 10.96, a P/E/G ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Truist Financial reissued a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday. Finally, Piper Sandler raised their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.